AveXis
Signal active
Organization
Contact Information
Overview
AveXis , doing business as Novartis Gene Therapies, Inc., is a biotechnology company that specializes in the development and commercialization of gene therapies for patients and families affected by rare and life-threatening neurological genetic diseases.
AveXis was acquired by Novartis on May 14, 2018. In 2020, the company was renamed Novartis Gene Therapies.
About
Industries
Biotechnology, Health Care, Medical, Genetics
Founded
2013
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
AveXis headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Genetics sector. The company focuses on Biotechnology and has secured $6.0B in funding across 80 round(s). With a team of 11-50 employees, AveXis is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - AveXis, raised $10.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
5
Investors
2
Lead Investors
0
Total Funding Amount
$75.1M
Details
4
AveXis has raised a total of $75.1M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2014 | Early Stage Venture | |||
| 2013 | Early Stage Venture | |||
| 2015 | Late Stage Venture | 65.0M | ||
| 2015 | Late Stage Venture | 10.0M |
Investors
AveXis is funded by 18 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| T. Rowe Price | - | FUNDING ROUND - T. Rowe Price | 65.0M |
| Jonathan Leff | - | FUNDING ROUND - Jonathan Leff | 65.0M |
| AveXis | - | FUNDING ROUND - AveXis | 65.0M |
| Deerfield | - | FUNDING ROUND - Deerfield | 65.0M |
Recent Activity
There is no recent news or activity for this profile.